Scotiabank raised the firm’s price target on BioMarin to $85 from $83 and keeps a Sector Perform rating on the shares following model adjustments. While the company’s enzyme business remains stable, in-line Voxzogo results and a struggling Roctavian franchise has led the firm to maintain its rating on the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
- Biomarin Pharmaceutical Inc. (BMRN) Q1 Earnings Cheat Sheet
- BioMarin participates in a conference call with JPMorgan.
- BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia